GlyProVac

Executive Summary

GlyProVac is a preclinical biotechnology company based in Copenhagen, Denmark, founded in 2007. The company is developing novel bacterial subunit vaccines using its patented BEMAP platform, which focuses on O-linked protein glycosylations. Its initial target is urinary tract infections (UTIs) and other diseases caused by Escherichia coli, aiming to combat antimicrobial resistance. Despite being in early preclinical stages, GlyProVac's BEMAP technology could offer a differentiated approach to vaccine design by leveraging specific glycan antigens to elicit targeted immune responses. The company's long development timeline and lack of disclosed funding or partnerships present significant risk, but the global need for effective UTI vaccines and the platform's potential applicability to other bacterial pathogens provide a compelling rationale for continued development.

Upcoming Catalysts (preview)

• 2027Preclinical proof-of-concept data in UTI animal models40% success
• TBDBEMAP platform licensing or collaboration deal20% success